Stocks Health care SRPT
NASDAQ · Health careSarepta Therapeutics, Inc. (SRPT)
Sarepta Therapeutics, Inc. brought in $2B of revenue over the twelve months to September 30, 2026, down 18.9% from a year earlier. It posted a net loss of $114.6M. In fiscal 2025 capital spending exceeded operating cash flow by $307.5M. At September 30, 2026 it held $472.8M in cash against $857.4M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 5, 2026.
Key facts about Sarepta Therapeutics, Inc.
- Net worth
- Sarepta Therapeutics, Inc. has a market value (market cap) of $1.7B at the latest share price, and shareholders' equity of $1.5B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $2.2B (+15.6% year on year), with a net loss of $713.4M. Over the 12 months to September 30, 2026: revenue $2B, net loss $114.6M.
- Cash flow
- In fiscal 2025 operations used $205.5M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 5, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Sarepta Therapeutics, Inc.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Sarepta Therapeutics, Inc. does
Sarepta Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker SRPT.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $2.2B | -$713.4M | -$7.13 | -$307.5M |
| 2024 | $1.9B | $235.2M | $2.34 | -$342.7M |
| 2023 | $1.2B | -$536M | -$5.80 | -$577.1M |
| 2022 | $933M | -$703.5M | -$8.03 | -$356.2M |
| 2021 | $701.9M | -$418.8M | -$5.15 | -$481.7M |
| 2020 | $540.1M | -$554.1M | -$7.11 | $25.3M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where SRPT ranks in Health care
Latest SEC filings
What Sarepta Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026
- November 5, 2026Quarterly report 10-Q · period to September 30, 2026Revenue fell 4.5% to $381.4M versus the same quarter last year; diluted EPS -$0.27 versus -$0.50.
- September 23, 2026Material agreement8-KSarepta Therapeutics entered into a settlement agreement with REGENXBIO, UPenn, and Catalent to resolve patent litigations.
- August 14, 2026Form 13F-HR filing 13F-HR
- August 13, 2026Passive stake changed SCHEDULE 13G/A
- August 7, 2026Passive stake (5% or more) SCHEDULE 13G
- August 5, 2026
- August 5, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 34% to $401.3M versus the same quarter last year; diluted EPS -$0.05 versus $1.89.
- July 31, 2026Passive stake changed SCHEDULE 13G/A
- July 30, 2026Passive stake changed SCHEDULE 13G/A
Insider trades
What the people running Sarepta Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 4 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 4, 2026 | Rodino-Klapac LouisePresident, R&D and Tech Ops | Shares withheld for tax | 21,423 | $476K |
| September 4, 2026 | Rothfuss CristinEVP, General Counsel | Shares withheld for tax | 22,025 | $489.4K |
| September 4, 2026 | Estepan Ian MichaelChief Operating Officer | Shares withheld for tax | 24,799 | $551K |
| September 4, 2026 | Wong Ryan Ho-YanChief Financial Officer | Shares withheld for tax | 13,272 | $294.9K |
| July 28, 2026 | Severino MichaelChief Executive Officer, Director | Received as pay | 756,104 | - |
| June 4, 2026 | Barry RichardDirector | Received as pay | 16,875 | - |
| June 4, 2026 | Chambers Michael AndrewDirector | Received as pay | 16,875 | - |
| June 4, 2026 | Nicaise ClaudeDirector | Received as pay | 16,875 | - |
Who owns SRPT
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Vanguard Portfolio Management13G, passive | 8.05% | July 31, 2026 |
| Vanguard Capital Management13G, passive | 5.11% | April 30, 2026 |
| AQR Capital Management, LLC13G, passive with 1 related filers | 5.05% | August 13, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 323 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 18,994,958 | +4,239,681 |
| State Street Corp | 8,916,090 | +2,302,776 |
| Vanguard Portfolio Management LLC | 8,377,470 | +1,736,778 |
| Two Sigma Investments, LP | 4,598,735 | +5,540 |
| Vanguard Capital Management LLC | 4,591,755 | +13,520 |
| First Trust Advisors LP | 4,365,951 | +230,163 |
| Aqr Capital Management LLC | 4,325,689 | -2,107,423 |
| Geode Capital Management, LLC | 2,771,758 | +782,962 |
| Erste Asset Management GmbH | 2,568,945 | -400,000 |
| Marshall Wace, Llp | 2,206,022 | +1,480,954 |
| Morgan Stanley | 2,202,641 | -394,352 |
| Aberdeen Group plc | 2,194,948 | -123,942 |
| Bank of America Corp | 2,055,985 | -89,941 |
| Goldman Sachs Group Inc | 2,042,501 | +964,249 |
| UBS Group AG | 1,624,415 | -608,044 |
| Federated Hermes, Inc. | 1,590,331 | -195,690 |
| Northern Trust Corp | 1,210,732 | +486,473 |
| Millennium Management LLC | 1,193,468 | -28,214 |
| Citigroup Inc | 1,155,006 | +7,358 |
| Renaissance Technologies LLC | 1,121,378 | -543,700 |
Insiders
14 insiders reported holding 5,685,707 shares in total, about $93.4M at the last price.
| Holder | Shares |
|---|---|
| Barry RichardDirector | 2,983,542 |
| Ingram Douglas SChief Executive Officer, Director | 929,391 |
| Severino MichaelChief Executive Officer, Director | 756,104 |
| Behrens M KathleenDirector | 214,357 |
| Rodino-Klapac LouisePresident, R&D and Tech Ops | 203,900 |
| Estepan Ian MichaelChief Operating Officer | 177,184 |
| Wong Ryan Ho-YanChief Financial Officer | 121,792 |
| Rothfuss CristinEVP, General Counsel | 115,519 |
| Nicaise ClaudeDirector | 48,407 |
| Wigzell Hans Lennart RudolfDirector | 42,098 |
Questions about SRPT
What does Sarepta Therapeutics, Inc. do?
Sarepta Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as SRPT. Its shares trade on NASDAQ under the ticker SRPT.
What is Sarepta Therapeutics, Inc.'s net worth?
Sarepta Therapeutics, Inc. has a market value (market cap) of $1.7B at the latest share price, and shareholders' equity of $1.5B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Sarepta Therapeutics, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $114.6M on revenue of $2B.
How much revenue does Sarepta Therapeutics, Inc. make?
Over the twelve months to September 30, 2026 Sarepta Therapeutics, Inc. reported revenue of $2B. That is 18.9% less than a year earlier.
When did Sarepta Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 5, 2026. It covers the period to September 30, 2026.
When is Sarepta Therapeutics, Inc.'s next earnings report?
Sarepta Therapeutics, Inc.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare SRPT with
Follow SRPT
Get an email when Sarepta Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Sarepta Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.